Skip to main content

Yu Jonathan Yen-Wen's Form 4 filing

Disc Medicine, Inc. (IRON) · filed Nov 13, 2025

Accession no.
0001193125-25-280766
Filed
Nov 13, 2025
Trade date
Nov 11, 2025
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 5 non-derivative transactions and 1 derivative transaction. Open-market sales total $2.54M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Yu Jonathan Yen-WenCIK 0001951849Officer (Chief Operating Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 11, 2025Common StockMOption exerciseAcquired+30,000$2.65+$79,50070,555Direct
Nov 11, 2025Common StockSSaleDisposed−8,015$83.15F2−$666,447.2562,540Direct
Nov 11, 2025Common StockSSaleDisposed−4,585$83.99F3−$385,094.1557,955Direct
Nov 11, 2025Common StockSSaleDisposed−9,360$85.33F4−$798,688.848,595Direct
Nov 11, 2025Common StockSSaleDisposed−8,040$85.91F5−$690,716.440,555Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 11, 2025Common StockMOption exerciseDisposed−30,000$0.00$07,941Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.63 to $83.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (5) to this Form 4.

Referenced by the price of 1 transaction in Table I.

F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.63 to $84.62, inclusive.

Referenced by the price of 1 transaction in Table I.

F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.69 to $85.68, inclusive.

Referenced by the price of 1 transaction in Table I.

F5

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.69 to $86.28, inclusive.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)